Citations 1
Phase III (IKEMA) study design: Isatuximab plus carfilzomib and dexamethasone (Kd) vs Kd in patients with relapsed/refractory multiple myeloma (RRMM).
Risse, Marie‐Laure , Asset, Gaëlle, Martin, Thomas G. , Dimopoulos, Meletios Α. , Yong, Kwee , Mıkhael, Joseph , Moreau, Philippe
Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: TPS8060-TPS8060
